A Spanish study from June 2024 suggests that two anti-hypertensive drugs are associated with a considerable reduction in the serious risk and mortality of COVID-19. They inhibit the RAS, as Jean-Marc Sabatier has always claimed.
Researchers evaluated the impact on Covid-19 of chronic treatment of hypertension with renin-angiotensin system (RAS) inhibitors: angiotensin I-converting enzyme inhibitor and AT1R receptor blocker/antagonist.
A study conducted in Galicia
The authors conducted a population-based case-control study in Galicia (northwestern Spain). Study data were obtained from medical, administrative and clinical databases.
The researchers assessed: (1) the risk of hospitalization, selecting all patients hospitalized due to COVID-19 with CRP – as cases, and a random sample of subjects without CRP – as controls; (2) the risk of COVID-19-related mortality; (3) the risk of disease progression; and (4) susceptibility to SARS-CoV-2, considering all patients with CRP – as cases, and the same subjects used in the previous model as controls.
Convincing results
The study demonstrated that ACIs and ARBs (first-line treatments for hypertension and chronic congestive heart failure) significantly reduce the risk of hospitalization and mortality.
The active substance enalapril (a member of the ACE inhibitor family, a substance responsible for arterial contraction, which increases blood pressure) was associated with a significantly lower risk of hospitalization. The use of candesartan [another antihypertensive belonging to the angiotensin II receptor antagonist family] was associated with less disease progression.
This large-scale, real-life, multi-population study from June 2024 demonstrates that RAS inhibitors (ACE inhibitors and sartan) protect against severe forms and mortality in COVID-19.
Jean-Marc Sabatier’s discoveries
The more time passes, the more scientists around the world confirm Jean-Marc Sabatier’s discoveries, published (and censored) right here since March-April 2020.
What did he discover?
